Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

Trouvé 1300 recommandations pour 634 médicaments et 133 équivalents thérapeutiques
Les médicaments retirés et les demandes rejetées ne sont pas indiqués. Les afficher.
  1. BCG vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Japanese encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Medicines for COVID-19 Informations générales
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
    COVID-19
  4. Abacavir Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  5. Abacavir + lamivudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  6. Abiraterone Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  7. Acamprosate calcium Informations générales
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
    Indications
    Disorders due to use of alcohol
  8. Acetazolamide Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  9. Acetic acid Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
    Indications
    Infectious diseases of external ear
  10. Acetylcysteine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  11. Acetylsalicylic acid Informations générales
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
  12. Acetylsalicylic acid + atorvastatin + ramipril Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  13. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  14. Aciclovir Informations générales
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Indications
    Zoster Varicella Herpes simplex infections
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
  15. Aclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  16. Activated charcoal Informations générales
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  17. Adalimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  18. Afatinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  19. Albendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    • Oral > Solid > tablet: 400 mg (chewable, scored))
    Indications
    Echinococcosis Ascariasis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
    Indications
    Other specified echinococcosis Cysticercosis of central nervous system
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Filariasis
  20. Alcohol based hand rub Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  21. All-trans retinoic acid Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  22. Allopurinol Informations générales
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  23. Alteplase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  24. Amidotrizoate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  25. Amikacin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neutropenia (high-risk) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe)
    Second choix
    co-prescrite avec cloxacillin Sepsis without septic shock
  26. Amiloride Informations générales
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  27. Amiodarone Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  28. Amitriptyline Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
  29. Amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  30. Amodiaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  31. Amodiaquine + sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
    Malaria
  32. Amoxicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    Premier choix
    Acute sinusitis Acute otitis media Acute pharyngitis Acute malnutrition in infants, children or adolescents (complicated) [children] Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
  33. Amoxicillin + clavulanic acid Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    Indications
    Premier choix
    Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Bacterial cellulitis, erysipelas or lymphangitis Acute sinusitis Peritonitis (mild-moderate) Infectious cystitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Chronic obstructive pulmonary disease with acute exacerbation
    Second choix
    Other specified prophylactic measures Acute otitis media Osteomyelitis or osteitis Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  34. Amphotericin B Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Blastomycosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis Aspergillosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Visceral leishmaniasis
  35. Ampicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
  36. Anastrozole Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  37. Anidulafungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  38. Ansuvimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  39. Anti-d immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Maternal care for red cell antibodies Rh incompatibility reaction
  40. Anti-rabies immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  41. Anti-rabies virus monoclonal antibodies Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  42. Anti-tetanus immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  43. Antivenom immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  44. Apixaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  45. Aprepitant Informations générales
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  46. Aripiprazole Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
  47. Arsenic trioxide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  48. Artemether Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  49. Artemether + lumefantrine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  50. Artesunate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  51. Artesunate + amodiaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  52. Artesunate + mefloquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  53. Artesunate + pyronaridine tetraphosphate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  54. Ascorbic acid Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  55. Asparaginase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  56. Atazanavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  57. Atenolol Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
  58. Atoltivimab + maftivimab + odesivimab Informations générales
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  59. Atorvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  60. Atorvastatin + perindopril + amlodipine Informations générales
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  61. Atracurium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Muscle relaxants Therapeutic equivalent to vecuronium pour Muscle relaxants
  62. Atropine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
  63. Azathioprine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 50 mg
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 50 mg (scored); 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  64. Azithromycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    • Oral > Solid > dosage form: 500 mg (anhydrous); 250 mg (anhydrous)
    Indications
    Premier choix
    Typhoid fever Trachoma Chlamydia trachomatis Yaws Paratyphoid fever co-prescrite avec ceftriaxone Gonococcal infection
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection
  65. Barium sulfate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  66. Beclometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  67. Beclometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  68. Bedaquiline Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  69. Bendamustine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  70. Benzathine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
    Indications
    Premier choix
    Syphilis Congenital syphilis [children]
  71. Benznidazole Informations générales
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
    Chagas disease
  72. Benzoyl peroxide Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  73. Benzyl benzoate Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pthiriasis Pediculosis corporis Pediculosis capitis Scabies
  74. Benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    Premier choix
    Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Bacterial meningitis
  75. Betamethasone Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus
  76. Bevacizumab Informations générales
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  77. Bicalutamide Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  78. Biperiden Informations générales
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  79. Bisacodyl Informations générales
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna pour Constipation
  80. Bisoprolol Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
  81. Bleomycin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
    Indications
    Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis
  82. Bortezomib Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  83. Bromocriptine Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands
  84. Budesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
    Asthma
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
    Indications
    Allergic rhinitis
  85. Budesonide + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
    Asthma
  86. Budesonide + salmeterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  87. Bumetanide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  88. Bupivacaine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
    Indications
    Local anaesthetics
  89. Buprenorphine Informations générales
    Section
    Medicines for opioid use disorders
    Indications
    Therapeutic equivalent to methadone pour Opioid dependence
  90. Bupropion Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
    Indications
    Nicotine dependence
  91. Cabergoline Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
  92. Caffeine citrate Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  93. Calamine Informations générales
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  94. Calcipotriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
    Indications
    Psoriasis of unspecified type
  95. Calcitriol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
  96. Calcium Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  97. Calcium folinate (leucovorin calcium) Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon
  98. Calcium gluconate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Hypermagnesaemia
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
  99. Canagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  101. Carbachol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
    Therapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma
  102. Carbamazepine Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Indications
    Epilepsy or seizures
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
    Indications
    Bipolar or related disorders
  103. Carbetocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  104. Carbimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole pour Thyrotoxicosis
  106. Carvedilol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  107. Caspofungin Informations générales
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin pour Systemic or invasive candidosis
  108. Cefalexin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
  109. Cefazolin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
  110. Cefixime Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection
  111. Cefotaxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritoneal abscess (severe)
    Second choix
    Acute pyelonephritis (mild to moderate) Osteomyelitis or osteitis Bacterial infection of joint Sepsis without septic shock Inflammatory and other diseases of prostate (mild to moderate)
  112. Ceftazidime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    Premier choix
    co-prescrite avec vancomycin Endophthalmitis
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic
  113. Ceftazidime + avibactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  114. Ceftolozane + tazobactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  115. Ceftriaxone Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Other specified pneumonia (Hospital-acquired pneumonia) Paratyphoid fever Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial meningitis co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec vancomycin Endophthalmitis
    Second choix
    Acute pyelonephritis (mild to moderate) Osteomyelitis or osteitis Inflammatory and other diseases of prostate (mild to moderate) Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent
  116. Cefuroxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choix
    Other specified prophylactic measures
  117. Certolizumab pegol Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  118. Cetirizine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  119. Chlorambucil Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  120. Chloramphenicol Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choix
    Bacterial meningitis
  121. Chlorhexidine Informations générales
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  122. Chlorine base compound Informations générales
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  123. Chloroquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium vivax Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
  124. Chlorothiazide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  125. Chloroxylenol Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  126. Chlorpromazine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
    Indications
    Therapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders
  127. Chlortalidone Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  128. Chlortetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  129. Cholera vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  130. Ciclesonide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  131. Ciclosporin Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  132. Ciprofloxacin Informations générales
    Section
    Watch group antibiotics
    • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    Indications
    Premier choix
    Paratyphoid fever Typhoid fever Acute pyelonephritis (mild to moderate) Neutropenia (low-risk) Infectious gastroenteritis or colitis without specification of infectious agent Inflammatory and other diseases of prostate (mild to moderate)
    Second choix
    Cholera [children] Cholera co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate)
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
  134. Cladribine Informations générales
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
    Indications
    Multiple sclerosis
  135. Clarithromycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid: 500 mg
    Indications
    Premier choix
    co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choix
    Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
  136. Clindamycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    Premier choix
    co-prescrite avec piperacillin + tazobactam Necrotising fasciitis
    Second choix
    Osteomyelitis or osteitis Bacterial infection of joint
  137. Clofazimine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Leprosy
  138. Clomifene Informations générales
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  139. Clomipramine Informations générales
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  140. Clopidogrel Informations générales
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  141. Clotrimazole Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  142. Cloxacillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis Bacterial infection of joint Osteomyelitis or osteitis
    Second choix
    co-prescrite avec amikacin Sepsis without septic shock
  143. Clozapine Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  144. Coagulation factor IX Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  145. Coagulation factor IX complex Informations générales
    Section
    Blood coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX pour Haemophilia B
  146. Coagulation factor VIII Informations générales
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 250 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  147. Coal tar Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  148. Codeine Informations générales
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
  149. Colecalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency
  150. Colistin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  151. Compound sodium lactate solution Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock
  153. Copper-containing intrauterine device Informations générales
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  154. Cryoprecipitate (pathogen-reduced) Informations générales
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Von Willebrand disease Obstetric haemorrhage
  155. Cyclizine Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
    Palliative care
  156. Cyclopentolate Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide pour Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine pour Anterior uveitis
  157. Cyclophosphamide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid: 25 mg; 50 mg
    • Oral > Solid: 25 mg; 50 mg tablet
    Indications
    Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  158. Cycloserine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  160. Dabigatran Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  161. Dacarbazine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  162. Daclatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
    Indications
    Chronic hepatitis C
  163. Daclatasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 60 mg + 400 mg
    Indications
    Chronic hepatitis C
  165. Dalteparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  166. Dapagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus
  167. Dapsone Informations générales
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  168. Darbepoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  169. Darunavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  170. Dasatinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  171. Daunorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities
  172. Deferasirox Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Therapeutic equivalent to deferoxamine pour Thalassaemias Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  173. Deferoxamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Thalassaemias Other specified sickle cell disorders or other haemoglobinopathies
  174. Delamanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  175. Dengue vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  176. Desmopressin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  177. Dexamethasone Informations générales
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Nausea or vomiting
  178. Dextran 70 Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  180. Diazepam Informations générales
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
    Palliative care
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
  181. Diazoxide Informations générales
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  182. Diethylcarbamazine Informations générales
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  183. Digoxin Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
    Heart failure
  184. Dihydroartemisinin + piperaquine phosphate Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  185. Diloxanide Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  186. Dimercaprol Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  187. Diphtheria antitoxin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  188. Diphtheria vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  189. Docetaxel Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate
  190. Docusate sodium Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
    Palliative care
  191. Dolasetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  192. Dolutegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  193. Dolutegravir + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  194. Dopamine Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Heart failure Cardiogenic shock
  195. Doxorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of breast Lymphoid leukaemia, not elsewhere classified Other specified malignant neoplasms of breast Diffuse large B-cell lymphomas Plasma cell myeloma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  196. Doxorubicin (as pegylated liposomal) Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  197. Doxycycline Informations générales
    Section
    Access group antibiotics
    • Oral > Solid: 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    Indications
    Premier choix
    Cholera Chlamydia trachomatis
    Second choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  198. Edoxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  199. Efavirenz Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  200. Efavirenz + emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  201. Efavirenz + lamivudine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  202. Eflornithine Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
    Indications
    African trypanosomiasis
  203. Empagliflozin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  204. Emtricitabine + tenofovir Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  205. Enalapril Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Heart failure
  206. Enoxaparin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  207. Entecavir Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  208. Enzalutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate
  209. Ephedrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  210. Epinephrine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Asthma Chronic obstructive pulmonary disease
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
  211. Epoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  212. Epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  213. Epoetin theta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  214. Equine rabies immunoglobulin Informations générales
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  215. Ergocalciferol Informations générales
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Therapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Vitamin D deficiency Calcium deficiency
  216. Ergometrine Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  217. Erlotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  218. Erythromycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    Chlamydial conjunctivitis Gonococcal infection of eye
    Section
    Watch group antibiotics
    Indications
    Second choix
    Therapeutic equivalent to clarithromycin pour Acute pharyngitis
  219. Erythropoiesis-stimulating agents Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  220. Estradiol cypionate + medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  221. Etanercept Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  222. Ethambutol Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
    Indications
    Tuberculosis
  223. Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  224. Ethambutol + isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  225. Ethanol Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  226. Ethinylestradiol + etonogestrel Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
    Indications
    Contact with health services for contraceptive management
  227. Ethinylestradiol + levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for contraceptive management
  228. Ethinylestradiol + norethisterone Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  229. Ethionamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis
  230. Ethosuximide Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  231. Etonogestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  232. Etoposide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  233. Everolimus Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
    Indications
    Other specified gliomas of brain
  234. Fentanyl Informations générales
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    Indications
    Chronic cancer pain
  235. Ferrous salt Informations générales
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
    Indications
    Iron deficiency anaemia
  236. Ferrous salt + folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  237. Fexinidazole Informations générales
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
  238. Fexofenadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type
  239. Filgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  240. Fluconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
    Indications
    Cryptococcosis Candidosis
  241. Flucytosine Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  242. Fludarabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  243. Fludrocortisone Informations générales
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  244. Flunisolide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  245. Fluorescein Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  246. Fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
    Dental caries
  247. Fluorouracil Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in vial
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon
  248. Fluoxetine Informations générales
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Social anxiety disorder Generalised anxiety disorder Panic disorder
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Obsessive-compulsive disorder
  249. Fluphenazine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  250. Flutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  251. Fluticasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  252. Fluticasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  253. Fluticasone furoate + vilanterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  254. Fluvastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  255. Folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
    Indications
    Folate deficiency anaemia Anencephaly or similar anomalies Spina bifida Cephalocele
  256. Fomepizole Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  257. Fosfomycin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  258. Fresh-frozen plasma Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  259. Furosemide Informations générales
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Anuria or oliguria Oedema
  260. Gefitinib Informations générales
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung
  261. Gemcitabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  262. Gentamicin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neonatal meningitis co-prescrite avec amoxicillin Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Sepsis without septic shock co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Sepsis without septic shock
    Second choix
    Other specified prophylactic measures Gonococcal infection
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
  263. Glass ionomer cement Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
    Dental caries
  264. Glatiramer acetate Informations générales
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
    Indications
    Multiple sclerosis
  265. Glecaprevir + pibrentasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
    Indications
    Chronic hepatitis C
  266. Gliclazide Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  267. Glucagon Informations générales
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
    Indications
    Hypoglycaemia in the context of diabetes
  268. Glucose Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes
  269. Glucose + sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  270. Glutaral Informations générales
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  271. Glyceryl trinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  272. Glycopyrronium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  273. Golimumab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  274. Goserelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  275. Granisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  276. Griseofulvin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  277. Haemophilus influenzae type b vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  278. Haloperidol Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  279. Haloperidol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders
  280. Halothane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  281. Heparin sodium Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  282. Hepatitis a vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  283. Hepatitis b vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  284. Homatropine Informations générales
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine pour Anterior uveitis
  285. Human papilloma virus (HPV) vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  286. Hydralazine Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Gestational hypertension
  287. Hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
    Oedema
  288. Hydrocortisone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Adrenocortical insufficiency
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Indications
    Crohn disease site Ulcerative colitis
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type
  289. Hydromorphone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  290. Hydroxocobalamin Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  291. Hydroxycarbamide (hydroxyurea) Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
    Section
    Cytotoxic medicines
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  292. Hydroxychloroquine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type
  293. Hyoscine butylbromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  294. Hyoscine hydrobromide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  295. Ibrutinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  296. Ibuprofen Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Pain
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Migraine
  299. Imipenem + cilastatin Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis
    Section
    Watch group antibiotics
    Indications
    Second choix
    Therapeutic equivalent to meropenem pour Neutropenia (high-risk) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe)
  300. Indapamide Informations générales
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide pour Heart failure
  301. Indometacin Informations générales
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen pour Patent arterial duct
  302. Infliximab Informations générales
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis
  303. Influenza vaccine (seasonal) Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  304. Insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  305. Insulin degludec Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  306. Insulin detemir Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  307. Insulin glargine Informations générales
    Section
    Insulins
    Indications
    Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus
  308. Intermediate-acting insulin Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus
  309. Intraperitoneal dialysis solution Informations générales
    Section
    Peritoneal dialysis solution
    • parenteral solution
    Indications
    Care involving peritoneal dialysis
  310. Iodine Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
    Indications
    Iodine deficiency
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine pour Povidone iodine
  311. Iohexol Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  312. Ipratropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
    Indications
    Asthma Chronic obstructive pulmonary disease
  313. Irinotecan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  314. Isoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  315. Isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
    Indications
    Tuberculosis
  316. Isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)
    Indications
    Tuberculosis
  317. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim Informations générales
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  318. Isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
    Tuberculosis
  319. Isoniazid + rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  320. Isosorbide dinitrate Informations générales
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  322. Ivermectin Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Indications
    Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Indications
    Onchocerciasis Lymphatic filariasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
  323. Kanamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  324. Ketamine Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  325. Lactulose Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
    Palliative care
  326. Lamivudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  328. Lamivudine + zidovudine Informations générales
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  329. Lamotrigine Informations générales
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Epilepsy or seizures
  330. Latanoprost Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  331. Ledipasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  332. Lenalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  333. Letrozole Informations générales
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
    Indications
    Female infertility without specification whether primary or secondary
  334. Leuprorelin Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  335. Levamisole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
    Ascariasis
  336. Levetiracetam Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
    Indications
    Epilepsy or seizures Status epilepticus
  337. Levodopa + benserazide Informations générales
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa pour Parkinson disease
  338. Levodopa + carbidopa Informations générales
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  339. Levofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  340. Levonorgestrel Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
  341. Levonorgestrel-releasing implant Informations générales
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  342. Levothyroxine Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  343. Lidocaine Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  344. Lidocaine + epinephrine Informations générales
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  345. Linezolid Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  346. Lisinopril + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  347. Lisinopril + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  348. Lithium carbonate Informations générales
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  349. Long-acting insulin analogues Informations générales
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  350. Loperamide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
    Palliative care
  351. Lopinavir + ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  352. Loratadine Informations générales
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 10 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  353. Lorazepam Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam pour Anxiety
  354. Losartan Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  355. Lovastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  356. Lugol's solution Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
    Thyrotoxicosis
  357. Magnesium sulfate Informations générales
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  358. Mannitol Informations générales
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  359. Measles vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  360. Mebendazole Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)
    Indications
    Other specified echinococcosis
  361. Medroxyprogesterone acetate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  362. Mefloquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  363. Meglumine antimoniate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  364. Meglumine iotroxate Informations générales
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  365. Melarsoprol Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    African trypanosomiasis
  366. Melphalan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  367. Meningococcal meningitis vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  369. Meropenem Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choix
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  370. Meropenem + vaborbactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  371. Mesalazine Informations générales
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis
  373. Metformin Informations générales
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  374. Methadone Informations générales
    Section
    Medicines for opioid use disorders
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
    Indications
    Chronic cancer pain
  375. Methimazole Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Thyrotoxicosis
  376. Methotrexate Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    • Oral > Solid: 2.5 mg (as sodium salt)
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Indications
    Psoriasis of unspecified type
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Juvenile idiopathic arthritis
  377. Methoxy polyethylene glycol-epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  378. Methyldopa Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Gestational hypertension
  379. Methylergometrine Informations générales
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine pour Postpartum haemorrhage
  380. Methylprednisolone Informations générales
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  381. Methylthioninium chloride Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  382. Metoclopramide Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  383. Metoprolol Informations générales
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol pour Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol pour Cardiac arrhythmia
  384. Metronidazole Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    Indications
    Premier choix
    co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritonitis (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate)
    Second choix
    co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) co-prescrite avec ciprofloxacin Peritonitis (mild-moderate)
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Amoebiasis
  385. Micafungin Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
    Indications
    Systemic or invasive candidosis
  386. Miconazole Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  387. Midazolam Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
    Palliative care
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Therapeutic equivalent to lorazepam pour Status epilepticus Status epilepticus
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
    Indications
    Sedative-hypnotic and anxiolytic drugs
  388. Mifepristone - misoprostol Informations générales
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Induced abortion Unspecified time of fetal death, cause not specified
  389. Miltefosine Informations générales
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  390. Misoprostol Informations générales
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
    Indications
    Spontaneous abortion, incomplete, without complication Unspecified obstetric condition Postpartum haemorrhage
  391. Mometasone Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide pour Asthma
  392. Mometasone + formoterol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol pour Asthma
  393. Morphine Informations générales
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Pain
  394. Moxifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    • Oral > Solid: 400 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculosis
  395. Multiple micronutrient powder Informations générales
    Section
    Vitamins and minerals
    • Oral > Other:
    Indications
    Iron deficiency anaemia
  396. Multiple micronutrient supplement Informations générales
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  397. Mumps vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  398. Mupirocin Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  399. Nadroparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  400. Naloxone Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  401. Naltrexone Informations générales
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
    Indications
    Disorders due to use of alcohol
  402. Natamycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  403. Neostigmine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    Indications
    Myasthenia gravis Anticholinesterase reversible
  404. Netilmicin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  405. Nevirapine Informations générales
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  406. Niclosamide Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  407. Nicotinamide Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  408. Nicotine replacement therapy Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum; 2 mg lozenge; 4 mg lozenge; 1 mg per actuation oral spray
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    Indications
    Nicotine dependence
  409. Nifedipine Informations générales
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
  410. Nifurtimox Informations générales
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)
    Indications
    African trypanosomiasis
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Chagas disease
  411. Nilotinib Informations générales
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  412. Nilutamide Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate
  413. Nitrofurantoin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Premier choix
    Infectious cystitis
  414. Nitrous oxide Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  415. Nivolumab Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  416. Norethisterone Informations générales
    Section
    Progestogens
    Indications
    Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle
  417. Norethisterone enantate Informations générales
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  418. Normal immunoglobulin Informations générales
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis
  419. Nystatin Informations générales
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
    Candidosis
  420. Octreotide Informations générales
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  421. Ofloxacin Informations générales
    Section
    Ear, nose and throat medicines [c]
    Indications
    Therapeutic equivalent to ciprofloxacin pour Infectious diseases of external ear
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Other specified conjunctivitis Infectious keratitis
  422. Olanzapine Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  423. Omeprazole Informations générales
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease Gastrointestinal bleeding
  424. Ondansetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
    Indications
    Nausea or vomiting
  425. Oral rehydration salts Informations générales
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  426. Oral rehydration salts - zinc sulfate Informations générales
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
    Diarrhoea
  427. Oseltamivir Informations générales
    Section
    Other antivirals
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  428. Oxaliplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  429. Oxamniquine Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
    Indications
    Schistosomiasis due to Schistosoma mansoni
  430. Oxycodone Informations générales
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine pour Pain
  431. Oxygen Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  432. Oxytetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma
  433. Oxytocin Informations générales
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  434. P-aminosalicylate sodium Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  436. Paliperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  437. Palonosetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  438. Pancreatic enzymes Informations générales
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
    Indications
    Enzyme intestinal
  439. Paracetamol (acetaminophen) Informations générales
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Pain
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Migraine
  440. Paromomycin Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
  441. Pegaspargase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  442. Pegfilgrastim Informations générales
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  443. Pembrolizumab Informations générales
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab pour Melanoma of skin
  444. Penicillamine Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  445. Pentamidine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
    Pneumocystosis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
    Indications
    African trypanosomiasis
  446. Permethrin Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  447. Pertussis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  448. Phenobarbital Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
    Indications
    Epilepsy or seizures Status epilepticus
  449. Phenoxymethylpenicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    Premier choix
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
  450. Phenytoin Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)
    Indications
    Epilepsy or seizures
  451. Phytomenadione Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants Haemorrhagic or haematological disorders of fetus or newborn
  452. Pilocarpine Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma
  453. Piperacillin + tazobactam Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    Premier choix
    Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis
  454. Platelets Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  455. Plazomicin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  456. Pneumococcal vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  457. Podophyllotoxin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin pour Anogenital warts Therapeutic equivalent to podophyllum resin pour Plantar warts
  458. Podophyllum resin Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Anogenital warts Plantar warts
  459. Poliomyelitis vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  460. Polygeline Informations générales
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    Indications
    Therapeutic equivalent to dextran 70 pour Hypovolaemia
  461. Polymyxin B (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  462. Potassium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
  463. Potassium ferric hexacyanoferrate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  464. Potassium iodide Informations générales
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
    Thyrotoxicosis
  465. Potassium permanganate Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo
  466. Povidone iodine Informations générales
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  467. Pravastatin Informations générales
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis
  468. Praziquantel Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Diphyllobothriasis Hymenolepiasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Cysticercosis of central nervous system
  469. Precipitated sulfur Informations générales
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate pour Pthiriasis Therapeutic equivalent to benzyl benzoate pour Pediculosis corporis Therapeutic equivalent to benzyl benzoate pour Pediculosis capitis Therapeutic equivalent to benzyl benzoate pour Scabies
  470. Prednisolone Informations générales
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Indications
    Therapeutic equivalent to hydrocortisone pour Crohn disease site Crohn disease site Ulcerative colitis
    Section
    Hormones and antihormones
    • Oral > Solid: 5 mg; 25 mg
    • Oral > Liquid: 5 mg per mL
    Indications
    Plasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
  471. Prednisone Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Follicular lymphoma Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to prednisolone pour Allergic or hypersensitivity conditions of unspecified type
  472. Pretomanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  473. Primaquine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium vivax
  474. Procaine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    Premier choix
    Congenital syphilis [children]
    Second choix
    Syphilis
  475. Procarbazine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  476. Progesterone vaginal ring Informations générales
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  477. Proguanil Informations générales
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  478. Propanol Informations générales
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol pour Denatured alcohol
  479. Propofol Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  480. Propranolol Informations générales
    Section
    Antimigraine medicines > For prophylaxis
    • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
    Indications
    Migraine
  481. Propylthiouracil Informations générales
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  482. Prostaglandin E1 Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct
  483. Prostaglandin E2 Informations générales
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Therapeutic equivalent to prostaglandin E1 pour Other specified congenital anomaly of great arteries including arterial duct
  484. Protamine sulfate Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants
  485. Protionamide Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis
  486. Pyrantel Informations générales
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
  487. Pyrazinamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg
    Indications
    Tuberculosis
  488. Pyridostigmine Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
    • Oral > Solid: 60 mg (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  489. Pyridoxine Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 25 mg (hydrochloride)
    Indications
    Vitamin B6 deficiency Sideroblastic anaemia Other specified polyneuropathy
  490. Pyrimethamine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  491. Quetiapine Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
    Indications
    Bipolar or related disorders
  492. Quinine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
    • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
    Indications
    Malaria due to Plasmodium falciparum
  493. Rabies vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  494. Raltegravir Informations générales
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  495. Ranitidine Informations générales
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Gastro-oesophageal reflux disease Peptic ulcer, site unspecified
  496. Rasburicase Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
    Indications
    Tumour lysis syndrome
  497. Ravidasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  498. Ready to use therapeutic food Informations générales
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
    Indications
    Acute malnutrition in infants, children or adolescents
  499. Realgar-indigo naturalis formulation Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  500. Red blood cells Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  501. Resin-based composite (high-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
    Dental caries
  502. Resin-based composite (low-viscosity) Informations générales
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
    Dental caries
  503. Retinol Informations générales
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
    • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
    • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
    Indications
    Vitamin A deficiency
  504. Ribavirin Informations générales
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  505. Riboflavin Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  506. Rifabutin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  507. Rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  508. Rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet; 300 mg tablet
    Indications
    Tuberculosis Latent tuberculosis
  509. Risperidone Informations générales
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    • Parenteral > General injections > IM:
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone pour Schizophrenia or other primary psychotic disorders
  510. Ritonavir Informations générales
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  511. Rituximab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  512. Rivaroxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  513. Rotavirus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  514. Rubella vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  515. Salbutamol Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
    • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
    Indications
    Chronic obstructive pulmonary disease Asthma
  516. Salicylic acid Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  517. Selenium sulfide Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  518. Senna Informations générales
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  519. Sevoflurane Informations générales
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  520. Silver diamine fluoride Informations générales
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
    Dental caries
  521. Silver sulfadiazine Informations générales
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  522. Simvastatin Informations générales
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
  523. Sodium calcium edetate Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  524. Sodium chloride Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  525. Sodium hydrogen carbonate Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  526. Sodium nitrite Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  527. Sodium nitroprusside Informations générales
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  528. Sodium stibogluconate Informations générales
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  529. Sodium thiosulfate Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  530. Sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg; 200 mg
    Indications
    Chronic hepatitis C
  531. Sofosbuvir + velpatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  532. Spectinomycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choix
    Gonococcal infection
  533. Spironolactone Informations générales
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Oedema Ascites
  534. Streptokinase Informations générales
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  535. Streptomycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  536. Succimer Informations générales
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  537. Sulfadiazine Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
  538. Sulfadoxine + pyrimethamine Informations générales
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria
  539. Sulfamethoxazole + trimethoprim Informations générales
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Pneumocystosis
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Premier choix
    Infectious cystitis
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent
  540. Sulfasalazine Informations générales
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema:
    Indications
    Crohn disease site Ulcerative colitis
  541. Sumatriptan Informations générales
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 50 mg
    Indications
    Migraine
  542. Suramin sodium Informations générales
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    African trypanosomiasis
  543. Surfactant Informations générales
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  544. Suxamethonium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
    Indications
    Muscle relaxants
  545. Tacalcitol Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type
  546. Tacrolimus Informations générales
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  547. Tamoxifen Informations générales
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  548. Tedizolid Informations générales
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus
  549. Telmisartan + amlodipine Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  550. Telmisartan + hydrochlorothiazide Informations générales
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  551. Tenofovir disoproxil fumarate Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  552. Terbinafine Informations générales
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  553. Terbutaline Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol pour Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol pour Asthma
  554. Terizidone Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis
  555. Testosterone Informations générales
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  556. Tetanus vaccine Informations générales
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  557. Tetracaine Informations générales
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  558. Tetracycline Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
  559. Thalidomide Informations générales
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  560. Thiamine Informations générales
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  561. Thiopental Informations générales
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
    Therapeutic equivalent to propofol pour Anaesthetics and therapeutic gases
  562. Tick-borne encephalitis vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  563. Timolol Informations générales
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Primary open-angle glaucoma Ocular hypertension
  564. Tinidazole Informations générales
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole pour Amoebiasis
  565. Tioguanine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  566. Tiotropium bromide Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
    Indications
    Chronic obstructive pulmonary disease
  567. Tobramycin Informations générales
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis
  568. Torasemide Informations générales
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide pour Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema
  569. Tranexamic acid Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  570. Trastuzumab Informations générales
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  571. Triamcinolone hexacetonide Informations générales
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
    Indications
    Juvenile idiopathic arthritis
  572. Triclabendazole Informations générales
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Fascioliasis Paragonimiasis
  573. Trihexyphenidyl Informations générales
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden pour Parkinson disease
  574. Trimethoprim Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    Premier choix
    Infectious cystitis
  575. Triptorelin Informations générales
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate
  576. Tropicamide Informations générales
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  577. Tropisetron Informations générales
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron pour Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron pour Nausea or vomiting
  578. Tuberculin, purified protein derivative Informations générales
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  579. Typhoid vaccine Informations générales
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  580. Ulipristal Informations générales
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  581. Umeclidinium Informations générales
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease
  582. Urea Informations générales
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
  583. Valaciclovir Informations générales
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir pour Zoster Therapeutic equivalent to aciclovir pour Varicella Therapeutic equivalent to aciclovir pour Herpes simplex infections
  584. Valganciclovir Informations générales
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid: 450 mg Tablet
    Indications
    Cytomegaloviral retinitis
  585. Valproic acid (sodium valproate) Informations générales
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Epilepsy or seizures Status epilepticus
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
    Indications
    Bipolar or related disorders
  586. Vancomycin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    Premier choix
    Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis
    Second choix
    Neutropenia (high-risk)
  587. Varenicline Informations générales
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Nicotine dependence
  588. Varicella vaccine Informations générales
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  589. Vecuronium Informations générales
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  590. Verapamil Informations générales
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
  593. Vinorelbine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site
  594. Voriconazole Informations générales
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  595. Warfarin Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
    Indications
    Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation
  596. Water for injection Informations générales
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  597. Whole blood Informations générales
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  598. Xylometazoline Informations générales
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  599. Yellow fever vaccine Informations générales
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  600. Zidovudine Informations générales
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 250 mg capsule; 300 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  601. Zinc sulfate Informations générales
    Section
    Medicines for diarrhoea
    • Oral > Solid: 20 mg
    Indications
    Diarrhoea
  602. Zoledronic acid Informations générales
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow
  603. Zuclopenthixol decanoate Informations générales
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders